In Colorectal Cancer, Chemo-Induced Volume Elevation Linked with Postoperative Complications
the Cancer Therapy Advisor take:
According to a new study published in the Journal of the American College of Surgeons, researchers have found that having liver metastases and receiving chemotherapy are associated with higher splenic volume in patients with metastatic colorectal cancer, and the splenic volume increase is independently linked with major postoperative complications following hepatic resection.
For the study, researchers enrolled 80 patients with metastatic colorectal cancer and liver metastases who underwent hepatic resection. Of those, half received chemotherapy for 6 months before surgery while the other half did not receive preoperative chemotherapy. The patients who received preoperative chemotherapy were also compared to a group of 40 patients with benign disease who underwent cholecystectomy and a group of 40 patients with untreated non-metastatic colorectal cancer.
Results showed that the study group had significantly higher splenic volumes compared with the patients with benign disease (p < 0.001) and the patients with non-metastatic disease (p < 0.05) before chemotherapy. After 6 months of chemotherapy, the study group's splenic volumes were even higher, and the elevation was linked with any complication during surgery (p < 0.01) and major postoperative complications (p < 0.05).
Furthermore, patients with a 39% or higher increase in splenic volume were statistically significantly more likely to develop major complications after hepatic resection (p < 0.01). Of note, the researchers found no association between splenic volume increase and change in platelet count.
Splenic volume increase is independently linked with major postoperative complications following hepatic resection.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer